Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives

Ovarian cancer is one of the most frequent solid tumor that shows clearly biphasic behaviour in response to chemotherapy, with the majority of patients who achieved complete remission after the first cycle of chemotherapy, and subsequently present a relapse which, in most cases, leads to death. Epithelial ovarian cancer (EOC) arises as a consequence of genetic alterations that affect the cells of the ovarian surface, which leads to changes that occur through the activation of oncogenes and inactivation of tumor suppressor genes. The progression of EOC is characterized by a series of combined epigenetic aberrations, including the most important of those determined by the loss of methylation of certain regions of DNA encoding genes such as Ras-association domain-containing family 1 [(RASSF1A) tumor suppressor], death-associated protein kinase [(DAPK) protein kinase associated with the regulation of apoptosis], human sulfatase- 1 [(hSulf-1) sulfatase, which plays a key role in the regulation of apoptosis], breast cancer 1 gene [(BRCA1) tumor suppressor gene, involved in the processes of DNA repair], and HOXA10 (gene required to promote many transcription factors). To date, accumulating evidence suggests that the initial clinical response is due primarily to the therapeutic efficacy of chemotherapy against differentiated cancer cells that constitute the bulk of the tumor, whereas the high rate of recurrence is thought to be due to remaining drug-resistant cells, biologically distinct, identified as cancer stem cells (CSC). Current efforts are focusing on genetic and cytological definition of CSC, to guide the development of new diagnostic, and therapeutic perspectives.

Epithelial ovarian cancer (EOC); Cancer stem cells (CSC); Initial ovarian cancer cells (OCICs).

[1] Scully R.E., Sobin L.H., (eds) Histological typing of ovarian tumours, volume 9. New York: Springer, 1999.

[2] Dubeau L.: “The cell of origin of ovarian epithelial tumours”. Lancet Oncol., 2008, 9, 1191.

[3] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA. Cancer J. Clin., 2013, 63, 11.

[4] Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Co-ebergh J.W.W., Comber H., et al.: “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012”. Eur. J. Cancer, 2013, 49, 1374.

[5] Bray F., Ren J.S., Masuyer E., Ferlay J.: “Estimates of global cancer prevalence for 27 sites in the adult population in 2008”. Int. J. Cancer, 2013, 132, 1133.

[6] Jelovac D., Armstrong D.K.: “Recent progress in the diagnosis and treatment of ovarian cancer”. CA. Cancer J. Clin., 2011, 61, 183.

[7] Fleming G.F., Ronnet B.M., Seidman J.: “Epithelial ovarian cancer”. In: Barakat R.R., Markman M., Randall M.E., (eds). Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2009, 763.

[8] Barakat R., Berchuck A., Markman M., Randall M.E., (eds). Princi-ples and practice of gynecologic oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2013.

[9] Whittemore A.S., Harris R., Itnyre J.: “Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collabo-rative Ovarian Cancer Group”. Am. J. Epidemiol., 1992, 136, 1212.

[10] Tortolero-Luna G., Mitchell M.F.: “The epidemiology of ovarian cancer”. J. Cell. Biochem. Suppl., 1995, 23, 200.

[11] Silverberg S.G.: “Histopathologic grading of ovarian carcinoma: a review and proposal”. Int. J. Gynecol. Pathol., 2000, 19, 7.

[12] Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Ger-shenson D.M., Silva E.G.: “Grading ovarian serous carcinoma using a twotier system”. Am. J. Surg. Pathol., 2004, 28, 496.

[13] Gershenson D.M., Sun C.C., Bodurka D., Coleman R.L., Lu K.H., Sood A.K., et al.: “Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant”. Gynecol. Oncol., 2009, 114, 48.

[14] Schmeler K.M., Sun C.C., Bodurka D.C., Deavers M.T., Malpica A., Coleman R.L., et al.: “Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum”. Gynecol. Oncol., 2008, 108, 510.

[15] Gershenson D.M., Sun C.C., Lu K.H., Coleman R.L., Sood A.K., Malpica A., et al.: “Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary”. Obstet. Gynecol., 2006, 108, 361.

[16] Wiegand K.C., Shah S.P., Al-Agha O.M., Zhao Y., Tse K., Zeng T., et al.: “ARID1A mutations in endometriosis associated ovarian car-cinomas”. N. Engl. J. Med., 2010, 363, 1532.

[17] Mackay H.J., Brady M.F., Oza A.M., Reuss A., Pujade-Lauraine E., Swart A.M., et al.: “Prognostic relevance of uncommon ovarian his-tology in women with stage III/IV epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2010, 20, 945.

[18] Brown E., Stewart M., Rye T., Al-Nafussi A., Williams A.R., Brad-burn M., et al.: “Carcinosarcoma of the ovary: 19 years of prospective data from a single center”. Cancer. 2004, 100, 2148.

[19] Cadron I., Leunen K., Van Gorp T., Amant F., Neven P., Vergote I.: “Management of borderline ovarian neoplasms”. J.C.O., 2007, 25, 2928.

[20] Leake J.K., Currie J.L., Rosenshein N.B., Woodruff J.D.: “Long term follow up of serous ovarian tumors of low malignant potential”. Gynecol. Oncol., 1992, 47, 150.

[21] Barnhill D.R., Kurman R.J., Brady M.F., Omura G.A., Yordan E., Given F.T., et al.: “Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study”. J.C.O., 1995, 13, 2752.

[22] Risch H.A.: “Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone”. J. Natl. Cancer. Inst., 1998, 90, 1774.

[23] Tuncer Z.S., Günalp S., Aksu T., Ayhan A.: “Benign epithelial ovarian tumors”. Eur. J. Gynaecol. Oncol., 1998, 19, 391.

[24] Kurian A.W., Balise R.R., McGuire V., Whittemore A.S.: “Histo-logic types of epithelial ovarian cancer: have they different risk factors?”. Gynecol. Oncol. 2005, 96, 520.

[25] Di Leo S., Benedetti Panici P.L., Bolis P.F., Di Re F., Pecorelli S., Sbiroli C.: “Linee Guida in Oncologia Ginecologica”. Avalaible at: http://web.tiscali.it/sigowolit/lineeguida.html

[26] Zanoio L., Barcellona E., Zacchè G.: “Patologia degli annessi”. Milano: Masson-Elsevier, 2013, 344.

[27] Goff B.A., Mandel L.S., Melancon C.H., Muntz H.G.: “Frequency of symptoms of ovarian cancer in women presenting to primary care clinics”. J.A.M.A., 2004, 291, 2705.

[28] Tortolero-Luna G., Mitchell M.F.: “The epidemiology of ovarian cancer”. J. Cell. Biochem. Suppl., 1995, 23, 200.

[29] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J.: “Cancer statistics, 2008”. CA. Cancer J. Clin., 2008, 58, 71.

[30] Liu C.M.: “Cancer of the ovary”. N. Engl. J. Med., 2005, 352, 1268.

[31] Lerner J.P., Timor-Tritsch I.E., Federman A., Abramovich G.: “Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system”. Am. J. Obstet. Gynecol., 1994, 170, 81.

[32] Husseinzadeh N.: “Status of tumor markers in epithelial ovarian can-cer has there been any progress? A review”. Gynecol. Oncol., 2011, 120, 152.

[33] Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: “The influ-ence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study”. Gynecol. Oncol., 1992, 47, 159.

[34] Chi D.S., Musa F., Dao F., Zivanovic O., Sonoda Y., Leitao M.M., et al.: “An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking sur-gery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)”. Gynecol. Oncol., 2012, 124, 10.

[35] Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P.: “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients”. Gynecol. Oncol., 1998, 71, 431.

[36] Inciura A., Simavicius A., Juozaityte E., Kurtinaitis J., Nadis-auskiene R., Svedas E., Kajenas S.: “Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients”. B.M.C. Cancer, 2006, 6, 153.

[37] Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., Thiel R. P.: “Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival”. Gynecol. Oncol., 1999, 72, 93.

[38] Morice P., Dubernard G., Rey A., Atallah D., Pautier P., Pomel C., et al.: “Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer”. J. Am. Coll. Surg., 2003, 197, 955.

[39] Sehouli J., Savvatis K., Braicu E.I., Schmidt S.C., Lichtenegger W., Fotopoulou C.: “Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis”. Int. J. Gynecol. Cancer, 2010, 20, 1331.

[40] Bristow R.E., Chi D.S.: “Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis”. Gynecol. Oncol., 2006, 103, 1070.

[41] Morrison J., Haldar K., Kehoe S., Lawrie T.A.: “Chemotherapy ver-sus surgery for initial treatment in advanced ovarian epithelial cancer”. Cochrane Library, 2012, 8:CD005343.

[42] “NCCN guidelines for Ovarian Cancer 2013”. Avalaible at: http://www.nccn.org/professionals/physician_gls/f_guidelines.a sp#site

[43] van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., et al.: “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer”. N. Engl. J. Med., 1995, 332, 629.

[44] Park J.Y., Eom J.M., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T., Nam J. H.: “Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer”. J. Surg. Oncol., 2010, 101, 418.

[45] Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., Oza A.M.: “Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic re-view with metaanalyses”. Cancer, 2007, 109, 692.

[46] Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C.: “Ovar-ian surface epithelium: biology, endocrinology, and pathology”. Endocr. Rev., 2001, 22, 255.

[47] Aunoble B., Sanches R., Didier E., Bignon Y.J.: “Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review)”. Int. J. Oncol., 2000, 16, 567.

[48] Ma L., Lai D., Liu T., Cheng W., Guo L.: “Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3”. Acta Biochim. Biophys. Sin. (Shanghai), 2010, 42, 593.

[49] Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K.: “Stem and pro-genitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer”. Cancer Res., 2005, 65, 3025.

[50] Yang X.Y., Yu H., Peng Z.L.: “Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line”. Arch. Gy-necol. Obstet., 2011, 284, 1241.

[51] Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., et al.: “Identification and characterization of ovarian cancer-initiat-ing cells from primary human tumors”. Cancer Res., 2008, 68, 4311.

[52] Balch C., Huang T.H., Brown R., Nephew K.P.: “The epigenetics of ovarian cancer drug resistance and resensitization”. Am. J. Obstet. Gynecol., 2004, 191, 1552.

[53] Strathdee G., Vass J.K., Oien K.A., Siddiqui N., Curto-Garcia J., Brown R.: “Demethylation of the MCJ gene in stage III/IV epithe-lial ovarian cancer and response to chemotherapy”. Gynecol. Oncol., 2005, 97, 898.

[54] Ibanez de Caceres I., Battagli C., Esteller M., Herman J.G., Dulaimi E., Edelson M.I., et al.: “Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovar-ian cancer patients”. Cancer Res., 2004, 64, 6476.

[55] Yuecheng Y., Hongmei L., Xiaoyan X.: “Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer”. Clin. Exp. Metastasis, 2006, 23, 65.

[56] Staub J., Chien J., Pan Y., Qian X., Narita K., Aletti G., et al.: “Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance”. Oncogene, 2007, 26, 4969.

[57] Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., et al.: “Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance”. Cell Cycle, 2009, 8, 158.

[58] Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., et al.: “CD133 expression defines a tumor initiating cell population in primary human ovarian cancer”. Stem Cells, 2009, 27, 2875.

[59] Yang H., Kong W., He L., Zhao J.J., O’Donnell J.D., Wang J., et al.: “MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN”. Cancer Res., 2008, 68, 425.

[60] Soslow R.A.: “Histologic subtypes of ovarian carcinoma: an overview”. Int. J. Gynecol. Pathol., 2008, 27, 161.

[61] Jones P.A., Baylin S.B.: “The epigenomics of cancer”. Cell, 2007, 128, 683.

[62] Mulero-Navarro S., Esteller M.: “Epigenetic biomarkers for human cancer: the time is now”. Crit. Rev. Oncol. Hematol., 2008, 68, 1.

[63] Paige A.J., Brown R.: “Pharmaco(epi)genomics in ovarian cancer”. Pharmacogenomics. 2008, 9, 1825.

[64] Leu Y.W., Rahmatpanah F., Shi H., Wei S.H., Liu J.C., Yan P.S., Huang T.H.: “Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation”. Cancer Res., 2003, 63, 6110.

[65] Li S.D., Zhang J.R., Wang Y.Q., Wan X.P.: “The role of microRNAs in ovarian cancer initiation and progression”. J. Cell Mol. Med., 2010, 14, 2240.

[66] Wu Q., Guo R., Lin M., Zhou B., Wang Y.: “MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2”. Gynecol. Oncol., 2011, 122, 149.

[67] Socha M.J., Said N., Dai Y., Kwong J., Ramalingam P., Trieu V., et al.: “Aberrant promoter methylation of SPARC in ovarian cancer”. Neoplasia, 2009, 11, 126.

[68] Lai J.P., Sandhu D.S., Shire A.M., Roberts L.R.: “The tumor sup-pressor function of human sulfatase 1 (SULF1) in carcinogenesis”. J. Gastrointest. Cancer, 2008, 39, 149.

[69] Lai J., Chien J., Staub J., Avula R., Greene E.L., Matthews T.A., et al.: “Loss of HSulf-1 up- regulates heparin-binding growth factor signaling in cancer”. J. Biol. Chem., 2003, 278, 23107.

[70] Li F., Lin B., Hao Y., Li Y., Liu J., Cong J., et al.: “Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors”. Int. J. Mol. Sci., 2010, 11, 3748.

[71] Kelly M.P., Lee S.T., Lee F.T., Smyth F.E., Davis I.D., Brechbiel M.W., Scott A.M.: “Therapeutic efficacy of 177Lu-CHX-A’’-DTPAhu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy”. Prostate, 2009, 69, 92.

[72] Kelly M.P., Lee F.T., Smyth F.E., Brechbiel M.W., Scott A.M.: “Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model”. J. Nucl. Med., 2006, 47, 716.

[73] Krug L.M., Milton D.T., Jungbluth A.A., Chen L.C., Quaia E., Pandit- Taskar N., et al.: “Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels”. J. Thorac. Oncol., 2007, 2, 947.

[74] Ween M.P., Hummitzsch K., Rodgers R.J., Oehler M.K., Ricciardelli C.: “Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides”. Clin. Exp. Metastasis, 2011, 28, 113.

[75] Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al.: “Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells”. Cancer Res., 2006, 66, 9339.

[76] Tomao F., Papa A., Rossi L., Strudel M., Vici P., Lo Russo G., Tomao S.: “Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities foran innovative approach”. J. Exp. Clin. Cancer Res., 2013, 32, 48.

[77] Berry N.B., Bapat S.A.: “Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype”. J. Ovarian Res., 2008, 1, 8.

[78] Conic I., Dimov I., Tasic-Dimov D., Djordjevic B., Stefanovic V.: “Ovarian epithelial cancer stem cells”. ScientificWorldJournal., 2011, 11, 1243.

[79] Latifi A., Abubaker K., Castrechini N., Ward A.C., Liongue C., Dobill F., et al.: “Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile”. J. Cell. Biochem., 2011, 112, 2850.

[80] Dalerba P., Clarke M.F.: “Cancer stem cells and tumor metastasis: first steps into uncharted territory”. Cell Stem Cell, 2007, 1, 241.

[81] Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., et al.: “Ovarian cancer side population defines cells with stem cell-like characteristics and Müllerian Inhibiting Substance responsiveness”. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 11154.

[82] McLean K., Gong Y., Choi Y., Deng N., Yang K., Bai S., et al.: “Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production”. J. Clin. Invest., 2011, 121, 3206.

[83] Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F.: “Prospective identification of tumorigenic breast cancer cells”. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3983.

[84] Heider K.H., Kuthan H., Stehle G., Munzert G.: “CD44v6: a target for antibody-based cancer therapy”. Cancer Immunol. Immunother.,2004, 53, 567.

[85] De Stefano I., Battaglia A., Zannoni G.F., Prisco M.G., Fattorossi A., Travaglia D., et al.: “Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts”. Cancer Chemother. Pharmacol., 2011, 68, 107.

[86] Casagrande F., Cocco E., Bellone S., Richter C.E., Bellone M., Todeschini P., et al.: “Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin”. Cancer, 2011, 117, 5519.

[87] Santin A.D., Cané S., Bellone S., Palmieri M., Siegel E.R., Thomas M., et al.: “Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin”. Cancer Res., 2005, 65, 4334.

[88] Stewart J.J., White J.T., Yan X., Collins S., Drescher C.W., UrbanN.D., et al.: “Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels”. Mol. Cell Proteomics, 2006, 5, 433.

[89] Alvero A.B., Montagna M.K., Holmberg J.C., Craveiro V., Brown D.A., Mor G.: “Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells”. Mol. Cancer Ther., 2011, 10, 1385.

[90] Chen J., Wang J., Chen D., Yang J., Yang C., Zhang Y., et al.: “Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cellsin three dimensional basement membrane extract scaffold versus two dimensional monocultures”. B.M.C. Cell Biol., 2013, 14, 7.

[91] Luo L., Zeng J., Liang B., Zhao Z., Sun L., Cao D., et al.: “Ovariancancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome”. Exp. Mol. Pathol., 2011, 91, 596.

[92] Schilder R.J., Sill M.W., Lee R.B., Shaw T.J., Senterman M.K., Klein-Szanto A.J., et al.: “Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2008, 26, 3418.

[93] Corbeil D., Röper K., Hellwig A., Tavian M., Miraglia S., Watt S.M., et al.: “The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions”. J. Biol. Chem., 2000, 32, 5512.

[94] Ferrandina G., Bonanno G., Pierelli L., Perillo A., Procoli A., MariottiA., et al.: “Expression of CD133-1 and CD133- 2 in ovarian cancer”. Int. J. Gynecol. Cancer, 2008, 18, 506.

[95] Silva I.A., Bai S., McLean K., Yang K., Griffith K., Thomas D., et al.: “Aldehyde dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that portend poor patient survival”. Cancer Res., 2011, 71, 3991.

[96] Chefetz I., Holmberg J.C., Alvero A.B., Visintin I., Mor G.: “Inhibition of Aurora A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway”. Cell Cycle, 2011, 10, 2206.

[97] Chen R., Alvero A.B., Silasi D.A., Kelly M.G., Fest S., Visintin I., et al.: “Regulation of IKKbeta by miR-199a affects NFkappaB activity in ovarian cancer cells”. Oncogene, 2008, 27, 4712.

[98] Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al.: “TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer”. Cancer Res., 2006, 66, 3859.

[99] Zhao W.H., Cheng J.X., Shi P.F., Huang J.Y.: “Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both in vitro and in vivo”. Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao., 2011,31, 903.

[100] Nijman H.W., van Diest P.J., Poort-Keesom R.J., von Mensdorff- Pouilly S., Verstraeten R.A., Kummer A., et al.: “T cell infiltration and MHC I and II expression in the presence of tumor antigens: an immunohistochemical study in patients with serous epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 94, 114.

[101] Weng D., Song B., Durfee J., Sugiyama V., Wu Z., Koido S., et al.: “Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells”. Int. J. Cancer, 2011, 129, 1990.